Souders Financial Advisors Purchases 222 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Souders Financial Advisors raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,309 shares of the pharmaceutical company’s stock after buying an additional 222 shares during the quarter. Souders Financial Advisors’ holdings in Vertex Pharmaceuticals were worth $583,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in VRTX. Advisor OS LLC raised its position in Vertex Pharmaceuticals by 4.4% in the first quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock worth $263,000 after purchasing an additional 23 shares in the last quarter. Costello Asset Management INC grew its stake in shares of Vertex Pharmaceuticals by 3.6% in the 2nd quarter. Costello Asset Management INC now owns 689 shares of the pharmaceutical company’s stock valued at $307,000 after purchasing an additional 24 shares during the period. Kovack Advisors Inc. raised its holdings in shares of Vertex Pharmaceuticals by 1.9% in the 2nd quarter. Kovack Advisors Inc. now owns 1,280 shares of the pharmaceutical company’s stock worth $570,000 after buying an additional 24 shares in the last quarter. Newman Dignan & Sheerar Inc. raised its holdings in shares of Vertex Pharmaceuticals by 3.3% in the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company’s stock worth $350,000 after buying an additional 25 shares in the last quarter. Finally, Eastern Bank lifted its position in shares of Vertex Pharmaceuticals by 1.6% during the 2nd quarter. Eastern Bank now owns 1,635 shares of the pharmaceutical company’s stock worth $728,000 after buying an additional 25 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on VRTX. Truist Financial set a $490.00 price objective on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Barclays upped their target price on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the stock an “equal weight” rating in a report on Tuesday. Leerink Partnrs raised shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 25th. Guggenheim decreased their price objective on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Finally, Stifel Nicolaus cut their target price on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating for the company in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $489.45.

Vertex Pharmaceuticals Stock Down 0.2%

Vertex Pharmaceuticals stock opened at $416.25 on Friday. The stock has a market cap of $106.72 billion, a price-to-earnings ratio of 29.75 and a beta of 0.36. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.88. The business’s 50-day simple moving average is $404.18 and its 200 day simple moving average is $430.46.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.22. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter last year, the firm earned $4.38 EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.